Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

251
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
251
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

214
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
214
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

401
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
401
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

335
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
335
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

460
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
460
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Wagner-Meerwein-Like Rearrangement Generates a Vinyl Group in the Biosynthesis of the Polychlorinated Lipopeptides Fischerazoles.

Angewandte Chemie (International ed. in English)·2026
Same author

Antibacterial drug discovery: challenges and preclinical promises from synthetic small molecules.

Chemical Society reviews·2026
Same author

Light-controlled inhibition of Gram-positive bacteria by photoswitchable amphiphilic lipids (PALs).

RSC medicinal chemistry·2026
Same author

Advanced Synthetic Methods in Modern Medicinal Chemistry.

Journal of medicinal chemistry·2026
Same author

Mechano-Biocatalytic Stereoselective Reduction of Ketones With Baker's Yeast Under Solvent-Minimized Conditions.

ChemSusChem·2026
Same author

From Epigenetic Regulation to Protein Degradation: Emerging Strategies for Anti-Infective Drug Discovery.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Sep 22, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.0K

Tuberculosis Drug Discovery: Challenges and New Horizons.

Guilherme F S Fernandes1, Andrew M Thompson2, Daniele Castagnolo1

  • 1Department of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, United Kingdom.

Journal of Medicinal Chemistry
|May 25, 2022
PubMed
Summary

Tuberculosis (TB) remains a major global health threat, causing millions of deaths annually. This review examines promising new TB drugs and highlights challenges in developing effective treatments to combat this ancient infectious disease.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K

Related Experiment Videos

Last Updated: Sep 22, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.0K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.7K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Drug Discovery

Background:

  • Tuberculosis (TB) is a leading infectious killer, claiming 1.5 million lives in 2020.
  • The World Health Organization (WHO) emphasizes the urgent need for new TB drugs.
  • Despite recent advances, few novel TB drug candidates successfully reach clinical development.

Purpose of the Study:

  • To critically review anti-TB compounds with proven in vivo efficacy against Mycobacterium tuberculosis from the last six years.
  • To identify key challenges and successful strategies in developing new TB drugs.
  • To outline the current global pipeline of TB drug candidates in clinical studies.

Main Methods:

  • Literature review of scientific publications on anti-TB compounds.
  • Analysis of in vivo efficacy data for Mycobacterium tuberculosis.
  • Assessment of clinical trial pipelines for TB drug candidates.

Main Results:

  • Hundreds of novel anti-TB molecules are reported annually, but few advance.
  • Compounds demonstrating significant in vivo efficacy are identified and reviewed.
  • Key hurdles in TB drug development and successful strategies are highlighted.

Conclusions:

  • A renaissance in TB drug discovery is underway, with numerous candidates in trials.
  • Overcoming development challenges is crucial for advancing new TB therapies.
  • Further research and investment are needed to address the global TB burden.